Any word on the development of the glycomimetic compounds assays?
Would be interested in a progress update.

DEAL FLOW FOCUS | GlycoMimetics $63M

Carbohydrate mimics (“glycomimetic” compounds) represent a potential
new class of drugs. Maryland-based GlycoMimetics (GMI) is developing
first-in-class candidates with an initial focus on inflammation,
cancer, and infectious disease. The lead compound, an acute anti-
inflammatory agent, recently completed Phase I trials.

Take a look at the blue chip investors backing GMI, the technology and
indications pursued at http://LifeScienceDealFlow.com

ABOUT

There are countless quality news sources that focus on Big Pharma;
Life Science Deal Flow focuses upon the – at times – overlooked pre-
commercial entity and works diligently to bring you the latest on
early-stage therapeutic, diagnostic and device companies – the news
breaking, the funds raised, the investors participating, the
technologies pursued, the trials designed, the data yielded, the
regulatory pathway pursued and the products and indications approved.

Subscribe via email or RSS at http://LifeScienceDealFlow.com

MASS Petroleum (OTCBB: MASP) Announces historical $403 million dollar
acquisition in the Western Canadian Basin. Last three month PPS avg
was 0.22 - Current pps is 0.025 - Fair Estimated Target Price of 0.15

The Basin includes existing production and undeveloped lands in the
oil rich provinces of Alberta and Saskatchewan, which also includes
the Girouxville area of northwestern Alberta.

www.masspetroleum.com
www.pinksheets.com

The commercial wells have produced a total amount of 94650 barrels
with an average daily production rate of 3155 barrels per day. Using
current pricing for crude oil at $70.00 per barrel, It is confirmed
that the new wells have generated $6.5 million in revenue or a
projected $120 million per year. Once all wells are fully operational,
they could yield a daily production rate of 15000 barrels per day.

On Oct 22, 10:58 am, arubenstein <ab.rubenst...@gmail.com> wrote: